Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, In
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
01:41pm, Monday, 08'th Jun 2026
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
07:00am, Friday, 05'th Jun 2026
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaborat
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
10:10am, Thursday, 04'th Jun 2026
Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.
Press Release: Sanofi launches 2026 global employee stock purchase plan
04:07am, Thursday, 04'th Jun 2026
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.
Sanofi Chooses Snowflake to Accelerate its AI-Powered Drug Development
09:08am, Tuesday, 02'nd Jun 2026
SAN FRANCISCO--(BUSINESS WIRE)-- #SnowflakeSummit--SNOWFLAKE SUMMIT 26 – Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's lea
FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug
11:01am, Friday, 29'th May 2026
Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms.
Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease
01:00am, Thursday, 28'th May 2026
Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug ap
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
01:15pm, Friday, 22'nd May 2026
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Sanofi: Information concerning the total number of voting rights and shares - April 2026
12:37pm, Tuesday, 19'th May 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
12:26pm, Tuesday, 19'th May 2026
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Sanofi says rare lung disease drug outperforms standard care in trial
03:36pm, Monday, 18'th May 2026
French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
My Top 5 Dividend Stocks For May
10:58pm, Saturday, 16'th May 2026
I highlight five dividend stocks—HTO, ES, SNY, NLY, and AMCR—trading below fair value, each with strong balance sheets and good potential growth prospects. Each stock is projected to deliver doubl
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
01:15pm, Wednesday, 13'th May 2026
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
